Research
Hormonal
Increased secretion of GLP-1 induced by delivering nutrients to lower parts of the small intestines explains weight loss and improvements in glycaemic control after bariatric surgery.
Bariatric surgery, such as Roux-en-Y gastric bypass, improves metabolic control partly by increasing GLP-1 secretion from the lower small intestine. This hormonal change contributes to weight loss and better blood sugar control.
ModerateQualifiesMEDIUM confidence
an increased secretion of GLP-1 induced by delivering nutrients to lower parts of the small intestines (rich in L cells) may be one factor (among others like peptide YY) explaining weight loss and improvements in glycaemic control after bariatric surgery (e.g., Roux-en-Y gastric bypass).
Why this rating
Described as 'one factor' and 'may indicate', suggesting less definitive causality than direct drug effects.
Source
Incretin hormones: Their role in health and disease
Michael A. Nauck et al. · Diabetes Obesity and Metabolism · 2018
DOI 10.1111/dom.13129
narrative_reviewCited 869×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Pharmacological stimulation of GLP-1 receptors significantly reduces plasma glucose and improves glycaemic control in subjects with type 2 diabetes by preserving insulinotropic and glucagonostatic effects.Good
- GLP-1 receptor agonists promote long-term weight loss by reducing appetite and food intake, primarily through effects on the hypothalamus.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →